Roche considering divesting $1.9 bln cancer data startup, FT reports

Swiss pharmaceutical company Roche (ROG.S) is considering divesting cancer data specialist Flatiron Health, the Financial Times reported on Wednesday, citing people familiar with the matter.
Roche had paid $1.9 billion for New-York based Flatiron Health in 2018 to speed its development of cancer medicines and support its efforts to price them based on how well they work.